Abstract 485P
Background
Integrins are known to play a crucial role in the adhesion, invasion and migration of tumor cells. Recent studies revealed the association of certain integrin subunits in organotropic metastasis of breast cancer. In this study, we investigated the biological properties associated with different integrin subunits gene expression in CTCs.
Methods
The study included 81 patients with non-metastatic invasive breast carcinoma of no special type (T1-4N0-3M0, all molecular subtypes). Single-cell cDNA libraries were prepared using the Single Cell 3′ Reagent Kit v3.1 and a 10x Genomics Chromium Controller. The ready cDNA libraries were sequenced on NextSeq 500 and NextSeq 2000 (Illumina, USA).
Results
CTCs were identified based on the expression of one or more epithelial markers: KRT5, 7, 8, 14, 18, EPCAM, MUC1 and CDH1 (E-cadherin). In total, expression of 14 integrin subunits was detected in CTCs: nine α-subunits and five β-subunits. In each cell, the combination of different integrin subunits was evaluated, and if complementary α and β-subunits gene expression detected in one cell, we suggested that CTCs potentially could synthesize functionally complete integrin heterodimers. Depending on the combinations of different subunits in CTCs, 455 cells were divided into nine groups. In each group, we assessed the proportion of cells with expression of genes relevant to the most important functions that determine the malignant potential of tumor cells: stemness, EMT, invasion. The most differences were observed in the group of CTCs potentially capable to express the α6β4 heterodimer. Namely, integrins α6- and β4-positive CTCs more frequent expressed stemness (ALDH1A1, CD133, KLF4, MYC) and invasion markers (RAC1, RHOC, ROCK, MMP1,2). A combination of epithelial (KRT 8, 10, 18, 19 and MUC1) with mesenchymal features (absence of EPCAM expression, expression of CDH2, VIM, ZEB1) indicates a hybrid state of EMT.
Conclusions
A novel approach to scRNA sequence analysis has identified subpopulations of CTCs with pronounced biological properties which can play role of "seeds". The simultaneously presence of integrin α6 and β4-subunits in CTCs was associated with stemness, EMT and invasiveness of CTCs in breast cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was supported by the Russian Science Foundation (grant #21-15-00140).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
457P - Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
Presenter: Gretchen Kimmick
Session: Poster session 04
458P - Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey
Presenter: Camilla Lisanti
Session: Poster session 04
460P - Impact of fulvestrant utilization on prognostic outcome among patients with HR+ve/HER2-ve metastatic breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 04
462P - Health outcomes of treatment sequences with eribulin or other single agents’ chemotherapy for treating relapsed metastatic HER2-negative breast cancer
Presenter: Simone Rivolo
Session: Poster session 04
463P - Impact of two waves of Sars-Cov-2 outbreak on the clinical presentation and outcomes of newly referred breast cancer cases at AP-HP: A retrospective multicenter cohort study
Presenter: Sonia Priou
Session: Poster session 04
464P - Developing a prognostic risk stratification model and treatment options for HER2-positive breast cancer brain metastasis
Presenter: JiaXin Chen
Session: Poster session 04
465P - Reporting of older subgroups enrolled to registration breast cancer trials, 2012-2021
Presenter: Colm Mac Eochagain
Session: Poster session 04